NCT02620306 - A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan | Biotech Hunter

Enrollment

351

Participants

Timeline

Start Date

February 11, 2016

Primary Completion Date

December 23, 2019

Study Completion Date

May 11, 2022

Conditions

Chronic Kidney Disease

Interventions

DRUG

Fimsartan 60mg~120mg

Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

DRUG

Fimsartan 60mg~120mg

Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

DRUG

Losartan 50mg~100mg

Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

DRUG

Losartan 50mg~100mg

Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

Trial Locations (1)

Unknown

Severance hospital, Seoul